Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?

por Cremolini, C, Ruzzo, A, Graziano, F, Falcone, A, Loupakis, F
Publicado 2010

Do we need biopsies of metastases for colorectal cancer patients?

por Floriani, I, Santini, D, Torri, V, Cremolini, C, Falcone, A, Loupakis, F
Publicado 2009

Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'

por Schirripa, M, Loupakis, F, Pollina, L, Cremolini, C, Pasquini, G, Falcone, A
Publicado 2013

Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

por Hofheinz, R.-D., Ronellenfitsch, U., Kubicka, S., Falcone, A., Burkholder, I., Hacker, U. T.
Publicado 2016

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer

por Sobrero, A, Frassineti, G, Falcone, A, Dogliotti, L, Rosso, R, Di Costanzo, F, Bruzzi, P
Publicado 2005

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer

por Sobrero, A, Frassineti, G, Falcone, A, Dogliotti, L, Rosso, R, Costanzo, F D, Bruzzi, P
Publicado 2005

Efficacy and safety of thalidomide in two sisters with severe refractory polyarteritis nodosa (PAN)

por Vitale, A, La Torre, F, Calcagno, G, Fede, C, Falcone, A, Ferraù, V, Falcini, F
Publicado 2008

Hypersensitivity reactions related to oxaliplatin (OHP)

por Brandi, G, Pantaleo, M A, Galli, C, Falcone, A, Antonuzzo, A, Mordenti, P, Di Marco, M C, Biasco, G
Publicado 2003

Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study

por Tibaldi, C, Prochilo, T, Russo, F, Pennucci, M C, Del Freo, A, Innocenti, F, Fabbri, A, Falcone, A, Conte, P F, Baldini, E
Publicado 2006

A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs

por Carrato, A., Falcone, A., Ducreux, M., Valle, J. W., Parnaby, A., Djazouli, K., Alnwick-Allu, K., Hutchings, A., Palaska, C., Parthenaki, I.
Publicado 2015

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer

por Galli, L, Fontana, A, Galli, C, Landi, L, Fontana, E, Antonuzzo, A, Andreuccetti, M, Aitini, E, Barbieri, R, Di Marsico, R, Falcone, A
Publicado 2007

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II...

por Tibaldi, C, Vasile, E, Antonuzzo, A, Di Marsico, R, Fabbri, A, Innocenti, F, Tartarelli, G, Amoroso, D, Andreuccetti, M, Dico, M Lo, Falcone, A
Publicado 2008

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients

por Scartozzi, M, Bearzi, I, Mandolesi, A, Giampieri, R, Faloppi, L, Galizia, E, Loupakis, F, Zaniboni, A, Zorzi, F, Biscotti, T, Labianca, R, Falcone, A, Cascinu, S
Publicado 2011

Study of SiPM custom arrays for scintillation light detection in a Liquid Argon Time Projection Chamber

por Cervi, T, Babicz, M E, Bonesini, M, Falcone, A, Kose, U, Nessi, M, Menegolli, A, Pietropaolo, F, Raselli, G L, Rossella, M, Torti, M, Zani, A
Publicado 2017

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab

por Loupakis, F, Schirripa, M, Caparello, C, Funel, N, Pollina, L, Vasile, E, Cremolini, C, Salvatore, L, Morvillo, M, Antoniotti, C, Marmorino, F, Masi, G, Falcone, A
Publicado 2013

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib

por Bocci, G, Falcone, A, Fioravanti, A, Orlandi, P, Di Paolo, A, Fanelli, G, Viacava, P, Naccarato, A G, Kerbel, R S, Danesi, R, Del Tacca, M, Allegrini, G
Publicado 2008

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

por Vasile, E, Masi, G, Fornaro, L, Cupini, S, Loupakis, F, Bursi, S, Petrini, I, Di Donato, S, Brunetti, I M, Ricci, S, Antonuzzo, A, Chiara, S, Amoroso, D, Andreuccetti, M, Falcone, A
Publicado 2009

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients

por Allegrini, G, Falcone, A, Fioravanti, A, Barletta, M T, Orlandi, P, Loupakis, F, Cerri, E, Masi, G, Di Paolo, A, Kerbel, R S, Danesi, R, Del Tacca, M, Bocci, G
Publicado 2008

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide

por Orlandi, P, Fontana, A, Fioravanti, A, Di Desidero, T, Galli, L, Derosa, L, Canu, B, Marconcini, R, Biasco, E, Solini, A, Francia, G, Danesi, R, Falcone, A, Bocci, G
Publicado 2013

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

por Loupakis, F, Cremolini, C, Fioravanti, A, Orlandi, P, Salvatore, L, Masi, G, Di Desidero, T, Canu, B, Schirripa, M, Frumento, P, Di Paolo, A, Danesi, R, Falcone, A, Bocci, G
Publicado 2011